Catégorie : Substances psychédéliques et therapeutique

Psychedelic drug use in healthy individuals : A review of benefits, costs, and implications for drug policy, James W.B. Elsey, 2017

Psychedelic drug use in healthy individuals : A review of benefits, costs, and implications for drug policy James W.B. Elsey Drug Science, Policy and Law, 2017, 3, 1-11 sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/2050324517723232   Abstract The potential of psychedelic drugs in the treatment of mental health problems is increasingly being recognized. However, relatively little thrust has been given to the suggestion that individuals without any mental health problems may benefit from using psychedelic drugs, and that they may have a right to do so. This review considers contemporary research into the use of psychedelic drugs in healthy individuals, including neurobiological and subjective effects. In line with findings suggesting positive [...]

Lire la suite

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future, Robin L Carhart-Harris and Guy M Goodwin, 2017

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future Robin L Carhart-Harris and Guy M Goodwin Neuropsychopharmacology, 2017, 42, 2105–2113 doi:10.1038/npp.2017.84; published online 17 May 2017 Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady [...]

Lire la suite

Predicting Responses to Psychedelics : A Prospective Study, Eline C. H. M. Haijen et al., 2018

Predicting Responses to Psychedelics : A Prospective Study Eline C. H. M. Haijen, Mendel Kaelen, Leor Roseman, Christopher Timmermann, Hannes Kettner, Suzanne Russ, David Nutt, Richard E. Daws, Adam D. G. Hampshire, Romy Lorenz  and Robin L. Carhart-Harris Frontiers in Pharmacology, 2018 doi: 10.3389/fphar.2018.00897   Abstract Responses to psychedelics are notoriously difficult to predict, yet significant work is currently underway to assess their therapeutic potential and the level of interest in psychedelics among the general public appears to be increasing. We aimed to collect prospective data in order to improve our ability to predict acute- and longer-term responses to psychedelics. Individuals who planned to take a [...]

Lire la suite

Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions, Frederick S. Barrett et al., 2017

Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions Frederick S. Barrett, Hollis Robbins, David Smooke, Jenine L. Brown and Roland R. Griffiths Frontiers in Psychology, 2017 ORIGINAL RESEARCH published: 25 July 2017 doi: 10.3389/fpsyg.2017.01238 Abstract Psilocybin is a classic (serotonergic) hallucinogen (“psychedelic” drug) that may occasion mystical experiences (characterized by a profound feeling of oneness or unity) during acute effects. Such experiences may have therapeutic value. Research and clinical applications of psychedelics usually include music listening during acute drug effects, based on the expectation that music will provide psychological support during the acute effects of psychedelic drugs, and [...]

Lire la suite

Beyond LSD : A Broader Psychedelic Zeitgeist during the Early to Mid-20th Century, Jacob S. Aday et al., 2019

Beyond LSD : A Broader Psychedelic Zeitgeist during the Early to Mid-20th Century Jacob S. Aday, M.S. , Emily K. Bloesch, Ph.D. , and Christopher C. Davoli, Ph.D. Journal of Psychoactive Drugs, 2019 https://doi.org/10.1080/02791072.2019.1581961   ABSTRACT During the 1950s and 1960s, there was a tremendous surge in research into the effects of psychedelic drugs. When discussing this period of research, the discovery of the psychoactive properties of LSD in 1943 is often presented as the main, and sometimes only, driving force of the boom in research. This “Great Person,” or “Great Chemical,” historiographical lens fails to acknowledge other factors that were fundamental in setting the stage [...]

Lire la suite

Emotional breakthrough and psychedelics : Validation of the Emotional Breakthrough Inventory, Leor Roseman, Robin Carhart-Harris et al., 2019

Emotional breakthrough and psychedelics : Validation of the Emotional Breakthrough Inventory Leor Roseman, Eline Haijen, Kelvin Idialu-Ikato, Mendel Kaelen, Rosalind Watts and Robin Carhart-Harris Journal of Psychopharmacology, 2019, 1–12 DOI: 10.1177/0269881119855974   Abstract Background : Psychedelic therapy is gaining recognition and the nature of the psychedelic experience itself has been found to mediate subsequent long-term psychological changes. Much emphasis has been placed on the occurrence of mystical-type experiences in determining long-term responses to psychedelics yet here we demonstrate the importance of another component, namely: emotional breakthrough. Methods : Three hundred and seventy-nine participants completed online surveys before and after a planned psychedelic experience. Items pertaining to emotional [...]

Lire la suite

The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity, Ido Hartogsohn, 2018

The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity Ido Hartogsohn Frontiers in Neurosciences, 06 March 2018 | https://doi.org/10.3389/fnins.2018.00129 Past research has demonstrated to the ability of psychedelics to enhance suggestibility, and pointed to their ability to amplify perception of meaning. This paper examines the existing evidence for the meaning-enhancing properties of psychedelics, and argues that the tendency of these agents to enhance the perception of significance offers valuable clues to explaining their reported ability to stimulate a variety of therapeutic processes, enhance creativity, and instigate mystical-type experiences. Building upon previous research, which suggested the potential role of [...]

Lire la suite

Peter Webster added a comment to the article : REBUS and the Anarchic Brain : Toward a Unified Model of the Brain Action of Psychedelicss, R. Carhart-Harris et al., 2019

Peter Webster added a comment to the article : REBUS and the Anarchic Brain : Toward a Unified Model of the Brain Action of Psychedelicss R. L. Carhart-Harris and K. J. Friston, Pharmacological Reviews, 2019,  71, 316–344 https://doi.org/10.1124/pr.118.017160 https://www.grecc.org/publications/ressources-documentaires/pharmacologie/rebus-and-the-anarchic-brain-toward-a-unified-model-of-the-brain-action-of-psychedelics-r-l-carhart-harris-and-k-j-friston-2019/ Prediction : ultimately you will find that the Salience Network has a far greater importance for understanding psychedelic experience than the DMN. See: Menon V. (2015) Salience Network. In: Arthur W. Toga, editor. Brain Mapping: An Encyclopedic Reference, vol. 2, p. 597. Academic Press: Elsevier. In Doors of Perception, Aldous Huxley writes, [I was seeing] a bunch of flowers shining with their own inner light and all but quivering under the [...]

Lire la suite

Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder, Thomas K. Brown et al., 2019

Ibogaine and Subjective Experience : Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder Thomas K. Brown, PhDa, Geoff E. Noller, PhDb, and Julie O. Denenberg, MAc Journal of Psychoactive Drugs, 2019 https://doi.org/10.1080/02791072.2019.1598603 ABSTRACT This article examines the therapeutic potential of ibogaine, a powerful oneiric alkaloid derived from Tabernanthe iboga, through exploring the subjective experiences of 44 participants from two observational treatment studies for opioid use disorder. Following treatment with ibogaine HCl, the participants (Mexico, n = 30; New Zealand, n = 14) completed the States of Consciousness Questionnaire (SCQ) to quantify the magnitude of their psychotropic experience. Participants were asked to provide [...]

Lire la suite

‘Magic Mushrooms’ Effective for Severe Depression – Medscape – Oct 20, 2017.

'Magic Mushrooms' Effective for Severe Depression Batya Swift Yasgur, MA, LSW Medscape, October 20, 2017 https://www.medscape.com/viewarticle/887384   Psilocybin, the psychoactive compound in “magic mushrooms,” is a promising intervention for patients with treatment-resistant depression (TRD) and appears to offer a rapid, sustained effect, new research shows. Investigators led by David Nutt, MD, PhD, professor of neuropsychopharmacology, Imperial College, London, United Kingdom, collected pre- and posttreatment fMRI data on the use of psilocybin in 19 patients with severe major depression who had failed to respond to conventional treatments. The patients experience dramatic improvements in depressive symptoms 1 day following treatment; close to half met criteria for full response at [...]

Lire la suite